FDA and Critical Path Institute Launch Lysosomal Diseases Pre-Consortium to Define Drug Development Standards

A one-year feasibility effort launched by FDA's Center for Drug Evaluation and Research (CDER) and the Critical Path Institute (C-Path) signals an early-stage but consequential shift in how data standards, measurement frameworks, and regulatory pathways for lysosomal diseases will be constructed, with direct implications for CMC strategy and clinical trial design at rare disease manufacturers.

The initiative, designated the Lysosomal Diseases Pre-Consortium, operates under CDER's Accelerating Rare disease Cures (ARC) Program. Its mandate during this exploratory phase is to assess whether a sustainable, multi-stakeholder consortium is viable. C-Path will coordinate input from academic institutions, pharmaceutical sponsors, patient advocacy groups, and non-governmental organizations to map the current development landscape, identify common unmet medical product development needs, and draft a governance and operations plan for the full consortium.

For regulatory affairs leads and QA directors working in rare disease portfolios, the pre-consortium structure matters because it precedes formal standards-setting. Landscape analyses conducted at this stage typically inform the data standards and endpoint frameworks that later appear in draft guidance. Sponsors developing enzyme replacement therapies or substrate reduction therapies for lysosomal storage disorders should treat this phase as an early signal of where evidentiary expectations are heading.

C-Path's role as an independent, nonprofit intermediary is relevant to how outputs will be positioned. Standards and methods generated through C-Path consortia are designed to meet the scientific evaluation criteria applied by FDA to safety and efficacy assessments, meaning any data standards emerging from this effort carry practical weight in submission packages, not merely academic interest.

The pre-consortium's scope includes generating a research plan focused on identified development gaps, which suggests that biomarker qualification, natural history data requirements, and trial design considerations for this heterogeneous disease class are all on the table. Lysosomal diseases encompass a broad range of enzyme deficiencies with variable phenotypes, a complexity that has historically complicated endpoint selection and comparator arm design in regulatory submissions.

Stakeholder engagement during the pre-consortium phase is explicitly invited by CDER, making this a window for industry participants to shape the research agenda before it crystallizes into formal consortium objectives.

The full consortium's viability determination is expected within twelve months of the pre-consortium launch, setting a near-term checkpoint for sponsors to monitor before adjusting rare disease development plans.

Source: FDA / CDER via FDA.gov Drugs RSS Feed, September 1, 2022.